Chasing Expedited and Equitable Treatment Access for Children with TB
Children should not wait for TB treatment.
Start sooner.
Go faster.
Children often gain access to new TB treatments years after adults. That delay is preventable. CHEETA is the research consortium that aims to start sooner and go faster so new treatments reach children in years, not decades.
Courtesy of Yagazie Emezi/Getty Images/Images of Empowerment. Some rights reserved.
Courtesy of Maheder Haileselassie Tadese/Getty Images/Images of Empowerment. Some rights reserved.
CHEETA is a research consortium accelerating access to new, life-saving tuberculosis treatments for children, cutting a delay that has stretched from 8 to 13 years down to under two.
The science exists. The system makes children wait.
New TB drugs reach adults years before they reach children. That gap is not a limit of science. It is a limit of how pediatric drug development is organized: trials start too late, are designed inefficiently, and lack coordination, shared infrastructure, and support.
When pediatric access lags behind adult access, children may spend years without the benefits of newer TB treatments that could improve effectiveness, safety, and shorten treatment duration.
1.2M
children and young adolescents developed TB in 2024
11%
of new TB infections are in children
16%
of TB deaths are among children
Source: WHO Global Tuberculosis Report 2025
Under 2 years
The goal: cut the wait for children to access new TB drugs from 8 to 13 years down to under two.
When new treatments reach children years earlier, scientific advances are translated into pediatric care more quickly, so children receive TB treatments that are safer, more effective, shorter, and easier to take than existing options.
One coordinated approach, built to move faster.
CHEETA is not a single study or a single drug. It is a shared approach that fixes the sources of delay directly, so many treatments can be evaluated for children more efficiently over time.
Engage developers early
Working with drug developers during their pediatric plans, so trials are designed right from the start and aligned with regulators.
Design smarter trials
Optimal trial design and innovative approaches like a platform trial maintain rigor while speeding trial completion once started.
Build shared infrastructure
One trial platform with coordinated, capable sites in high-burden settings, that can evaluate multiple drugs over time, cutting duplication and speeding evidence.
Find your way in.
Different people come to CHEETA for different reasons. Each of these leads straight to what matters most for that group.
For funders
The opportunity, the evidence, and the impact of supporting a practical solution to persistent bottlenecks in pediatric TB drug development.
For TB drug developers
How CHEETA de-risks and speeds your pediatric development pathway.
For researchers and sites
The model, participation criteria, and how to take part in upcoming studies.
For communities and advocates
What the work means for children, and how to stay involved.
Already in motion.
CHEETA is co-led by Stellenbosch University and the University of Wisconsin-Madison, with the groundwork for trials well underway.
Trial site mapping and assessment
Building a clear picture of current pediatric TB trial capacity and untapped potential, across high-burden settings.
Optimizing the science and trial design
Generating consensus on optimal pediatric trial design to limit delays.
Stakeholders engaged
Active engagement with key stakeholders like the World Health Organization, regulators, researchers, and communities to shape efficient trial pathways.
A formal consortium
Established in 2025 and co-led by two major universities, evolving from the original task force.
On the world stage
Presented at major scientific meetings, including the Union World Conference on Lung Health.
A consortium built to deliver.
CHEETA brings together scientists, trialists, clinical sites, advocates, regulators, and pharmaceutical partners, the full ecosystem needed to make faster pediatric trials a reality.
The team carries deep, broad expertise in pediatric TB, clinical trials, pharmacometrics, and global health, a combination that is difficult to replicate.
Co-led by Stellenbosch University and the University of Wisconsin-Madison
See yourself in this work.
Whether you fund, partner, research, or advocate, there is a clear role for you in getting children the treatments they need sooner.
Chasing Expedited and Equitable Treatment Access for Children with TB. A global research consortium accelerating pediatric TB drug development.
Co-led by Stellenbosch University and the University of Wisconsin-Madison
© 2026 CHEETA Consortium